Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Moshit Lindzen

1PUBLICATIONS

37CO-AUTHORS

Molecular targets

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (1)

Sort by Publication Date:

|Jul 27, 2022

AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.

Ashish Noronha, Nishanth Belugali Nataraj, Joo Sang Lee

Pageof 1

Frequent Collaborators

1 joint publications

Ashish Noronha

1 joint publications

Nishanth Belugali Nataraj

1 joint publications

Joo Sang Lee

1 joint publications

Benny Zhitomirsky

1 joint publications

Yaara Oren

1 joint publications

Sara Oster

1 joint publications

Saptaparna Mukherjee

1 joint publications

Rainer Will

1 joint publications

Arturo Simoni-Nieves

1 joint publications

Aakanksha Verma

Frequent Collaborators

1 joint publications

Ashish Noronha

1 joint publications

Nishanth Belugali Nataraj

1 joint publications

Joo Sang Lee

1 joint publications

Benny Zhitomirsky

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos